📰 Inflammatory Disorders News
Page 2 - Inflammatory Disorders News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Inflammatory Disorders. Real-time updates on events, politics, business and more.
January 13, 2023
Tezspire approved for self-administration in the EU in a new pre-filled pen New administration option for first and only severe asthma biologic approved in the EU with no phenotype or biomarker limitations AstraZeneca’s Tezspire (tezepelumab) has received a positive opinion from the Europea...
November 29, 2022
The factors that are expected to act as drivers for the growth of the global exosome therapeutics market are the increased incidence of chronic...
November 29, 2022
A Qualitative Research Study accomplished by Data Bridge Market researchs database titled "Exosome Therapeutics Market" with 100+ market data Tables, Pie
November 22, 2022
JERSEY CITY, N.J., Nov. 22, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on "Global Clinical Trial Planning and Design Services Market
November 22, 2022
/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on "Global Clinical Trial Planning and Design Services Market...
October 26, 2022
/CNW/ - Today, AstraZeneca and Amgen announced the Canadian availability of Tezspire™ (tezepelumab injection), indicated for the add-on maintenance treatment...
September 12, 2022
A recent study published in Diagnostics identifies multimodal imaging traits to distinguish primary inflammatory choriocapillaropathies, such as multiple evanescent white dot syndrome and idiopathic multifocal choroiditis, from primary photoreceptoritis.
July 26, 2022
AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The ...
July 25, 2022
First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations. AstraZenecas Tezspire has been recommended for marketing authorisation... | July 25, 2022
February 26, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed...